Altus Pharmaceuticals Inc.

Form 3

October 15, 2007

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB APPROVAL** 

**OMB** Number:

3235-0104

Expires:

January 31,

Estimated average burden hours per

response...

2005

0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES** 

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*

Gotwals Philip

(Last)

125 SIDNEY STREET

(First)

(Middle)

Statement

(Month/Day/Year)

10/12/2007

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Altus Pharmaceuticals Inc. [ALTU]

4. Relationship of Reporting

Person(s) to Issuer

5. If Amendment, Date Original Filed(Month/Day/Year)

(Check all applicable)

10% Owner Director \_X\_\_ Officer Other (give title below) (specify below)

VP of Project Management

6. Individual or Joint/Group Filing(Check Applicable Line) \_X\_ Form filed by One Reporting

Person

Form filed by More than One

Reporting Person

CAMBRIDGE, Â MA Â 02139

(Street)

(City) (State) (Zip)

1. Title of Security (Instr. 4)

2. Amount of Securities Beneficially Owned

(Instr. 4)

Table I - Non-Derivative Securities Beneficially Owned

Ownership Form:

Direct (D) or Indirect (I)

4. Nature of Indirect Beneficial Ownership (Instr. 5)

(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

> Persons who respond to the collection of information contained in this form are not

required to respond unless the form displays a currently valid OMB control number.

SEC 1473 (7-02)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and **Expiration Date** (Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)

4. Conversion or Exercise Price of

5. Ownership Form of Derivative

6. Nature of Indirect Beneficial Ownership (Instr. 5)

Expiration Date Exercisable Date

Title

Security Amount or Number of

Shares

Derivative Security: Direct (D) or Indirect (I) (Instr. 5)

1

#### Edgar Filing: Altus Pharmaceuticals Inc. - Form 3

Stock Option (Right to buy)	(1)	09/25/2016	Common Stock	45,000	\$ 16.36	D	Â
Stock Option (Right to buy)	(2)	03/02/2017	Common Stock	5,738	\$ 14.24	D	Â

## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Gotwals Philip 125 SIDNEY STREET CAMBRIDGE Â MAÂ 02139	Â	Â	VP of Project Management	Â		

# **Signatures**

/s/ Kevin M.
Brennan

\_\*\*Signature of Reporting Person

Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These options began vesting on September 25, 2006. All of such options have a term of ten years vesting over four years, with 1/16th of the options vesting every three months. All of such options become exercisable as they vest.
- (2) These options began vesting on March 2, 2007. All of such options have a term of ten years vesting over four years, with 1/16th of the options vesting every three months. All of such options become exercisable as they vest.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2